This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 12496 results found since Jan 2013.

Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder
CONCLUSIONS: Further research should explore how to integrate employment support into OUD treatment to improve patient outcomes, particularly among women.SCIENTIFIC SIGNIFICANCE: The current study addressed gaps in the literature by examining sex differences in MOUD initiation and diverse treatment outcomes in a large, national sample.PMID:37583120 | DOI:10.1111/ajad.13463
Source: American Journal on Addictions - August 16, 2023 Category: Addiction Authors: Margaret Paschen-Wolff Shelly F Greenfield R Kathryn McHugh Kathleen Burlew Martina Pavlicova Tse-Hwei Choo Celestina Barbosa-Leiker Lesia M Ruglass Sarah Mennenga John Rotrosen Edward V Nunes Aimee N C Campbell Source Type: research

Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder
ConclusionsThis population PK model supports the use of CAM2038 doses as individualized treatment for OUD across different treatment stages, including initiation, switching from SL BPN according to established dose conversion schedules, and tapering.Trial RegistrationsISRCTN41550730 (05/19/2014), ISRCTN24987553 (07/29/2014), NCT02611752 (11/23/2015), NCT02710526 (03/16/2016).
Source: Clinical Pharmacokinetics - August 16, 2023 Category: Drugs & Pharmacology Source Type: research

BUPRENORPHINE AND NALOXONE (buprenorphine hydrochloride and naloxone hydrochloride) tablet Golden State Medical Supply, Inc.
Updated Date: Tue, 15 Aug 2023 00:00:00 EDT
Source: DailyMed Drug Label Updates - August 15, 2023 Category: Drugs & Pharmacology Source Type: alerts

Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia
Conditions:   Analgesia;   Abuse Opioids;   Pain Interventions:   Drug: Buccal Buprenorphine 300 mcg;   Drug: Buccal Buprenorphine 600 mcg;   Drug: Buccal Buprenorphine 900 mcg;   Drug: Buccal Placebo;   Drug: Oral Placebo;   Drug: Oral immediate-release oxycodone 10mg Sponsors:   Vanderbilt University Medical Center;   National Institute on Drug Abuse (NIDA) Not yet recruiting
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials